- Home
- MXCT vs DIBS Comparison
MXCT vs DIBS Comparison
Compare MXCT & DIBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MXCT | DIBS |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | United States |
| Employees | 91 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.0M | 153.0M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MXCT | DIBS |
|---|---|---|
| Price | $1.24 | $5.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 1 |
| Target Price | $5.50 | ★ $7.00 |
| AVG Volume (30 Days) | ★ 932.0K | 161.2K |
| Earning Date | 05-12-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 22.45 |
| EPS | ★ N/A | N/A |
| Revenue | $33,026,000.00 | ★ $89,620,000.00 |
| Revenue This Year | N/A | $3.12 |
| Revenue Next Year | $18.50 | $1.72 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.54 |
| 52 Week Low | $0.64 | $2.50 |
| 52 Week High | $2.37 | $6.62 |
Technical Indicators
Market Signals| Indicator | MXCT | DIBS |
|---|---|---|
| Relative Strength Index (RSI) | 65.10 | 70.66 |
| Support Level | $0.77 | $4.92 |
| Resistance Level | $1.30 | $6.18 |
| Average True Range (ATR) | 0.07 | 0.25 |
| MACD | 0.00 | 0.12 |
| Stochastic Oscillator | 68.00 | 97.72 |
Price Performance
Historical ComparisonAbout MXCT MaxCyte Inc.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
About DIBS 1stdibs.com Inc.
1stdibs.com Inc is an online marketplace for connecting design lovers with the sellers and makers of vintage, antique, and contemporary furniture, home decor, jewelry, watches, art, and fashion. The company has a single reportable and operating segment that contains one reporting unit, which consists of the company's online marketplace that enables commerce between sellers and buyers. The company generates maximum revenue from fees from seller marketplace services and other services, including advertisements.